Pronutria Biosciences Announces Jennifer Che, J.D., as Vice President, Intellectual Property Counsel

Pronutria Biosciences Announces Jennifer Che, J.D., as Vice President, Intellectual Property Counsel

November 5, 2015

Cambridge, Mass., November 5th, 2015 / BUSINESS WIRE / -- Pronutria Biosciences™ Inc., a biotechnology company pioneering a new class of therapeutics to mediate amino acid biology, announced today the appointment of Jennifer Che, J.D., as Vice President, Intellectual Property Counsel. Ms. Che will oversee all intellectual property activities related to the protection of Pronutria’s technology and lead candidates.

Acceleron Pharma Reports Third Quarter 2015 Financial and Operational Results

Acceleron Pharma Reports Third Quarter 2015 Financial and Operational Results

November 4, 2015

- ACE-083 Phase 1 results demonstrate an unprecedented increase in muscle volume. Phase 2 clinical trials planned to start next year -

- ACE-2494 generates significant increases in muscle mass in preclinical studies. Phase 1 clinical trial of ACE-2494 planned to start next year -

- FDA granted Fast Track Designation for dalantercept in combination with axitinib for the treatment of patients with advanced renal cell carcinoma -

Flagship Ventures Launches Evelo Therapeutics To Develop Microbiome Therapies for Cancer

Flagship Ventures Launches Evelo Therapeutics To Develop Microbiome Therapies for Cancer

November 4, 2015

Breakthrough Innovations from Flagship VentureLabs Target the Cancer Microbiome

Industry Leader Simba Gill Ph.D. Appointed CEO

Cambridge, Mass., Nov. 4, 2015/PRNewswire/ -- Flagship Ventures, a leading venture capital and venture creation firm focused on innovations in healthcare and sustainability, announced it has launched Evelo Therapeutics, a new company focused on leveraging the power of the microbiome to develop novel therapies for cancer, with an initial capital commitment of $35 million.

China Food and Drug Administration (CFDA) Grants Approval for Avedro’s KXL® System

China Food and Drug Administration (CFDA) Grants Approval for Avedro’s KXL® System

November 3, 2015

Avedro is the first and only company to receive CFDA approval for corneal cross-linking

T2 Biosystems Appoints Chief Commercial Officer

T2 Biosystems Appoints Chief Commercial Officer

November 3, 2015

LEXINGTON, Mass., Nov. 3, 2015 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a company developing innovative diagnostic products to improve patient health, today announced the appointment of veteran healthcare commercialization executive, David P. Harding, as the Company's chief commercial officer (CCO), effective immediately.

T2 Biosystems Announces Leading Hospitals Adopting T2Candida for Sepsis Detection

T2 Biosystems Announces Leading Hospitals Adopting T2Candida for Sepsis Detection

October 29, 2015

Adoption Driven by Need to Improve Sepsis Outcomes, Reduce Costs

TARIS Biomedical® Raises $32 Million and Expands Leadership Team and Board of Directors

TARIS Biomedical® Raises $32 Million and Expands Leadership Team and Board of Directors

October 27, 2015

TARIS® emerges, after the sale of its lead asset to Allergan, as a new company focused on developing a broad portfolio of urology products

Initial focus on bladder cancer and overactive bladder, using TARIS’ novel drug-device combination approach

Christopher Cutie, M.D., joins as VP, Clinical Development, and health care industry veterans Kevin Finney and Mark Iwicki join TARIS’ board of directors

Acceleron Highlights Phase 3 Studies, New Clinical Results and Research Strategies at Research and Development Day Event

Acceleron Highlights Phase 3 Studies, New Clinical Results and Research Strategies at Research and Development Day Event

October 23, 2015

- Phase 3 Studies in Myelodysplastic Syndromes ("MEDALIST") and Beta-thalassemia ("BELIEVE") Outlined -

- ACE-083 Preliminary Phase 1 Results Demonstrate 14% Increase in Muscle Volume -

- Acceleron Unveils IntelliTrap™ Platform to Design New Class of Highly Selective Inhibitors of TGF-beta Superfamily Ligands -

Moderna Launches Caperna LLC, Its Fourth Venture, to Develop Personalized Cancer Vaccines

Moderna Launches Caperna LLC, Its Fourth Venture, to Develop Personalized Cancer Vaccines

October 22, 2015

Caperna developing personalized cancer vaccines in combination with other cancer immunotherapies. Moderna finalizing the development of rapid cycle-time, small-batch GMP capabilities to support the development of personalized therapies.

Syros Pharmaceuticals Appoints Industry Leader Marsha H. Fanucci to Its Board of Directors

Syros Pharmaceuticals Appoints Industry Leader Marsha H. Fanucci to Its Board of Directors

October 19, 2015

Scientific Co-Founder James E. Bradner Steps Down from Board Following Appointment as President of NIBR

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals, the industry pioneer in gene control, today announced the appointment of Marsha H. Fanucci to the company’s Board of Directors. Ms. Fanucci brings 25 years of experience in biopharmaceutical financial management and strategic business operations.